E·LUMINEXX™
VASCULAR & BILIARY STENT



Designed for Endurance and Delivering

VISIBLE RESULTS



BARD PERIPHERAL VASCULAR

E•LUMINEXX™
BILIARY STENT

LABORATORY TEST OUTCOMES

Comparative Stent Fatigue Survival Rates

Axial Compression & Compression / Elongation Tests



Biliary Stent Surface Finish Comparison

SEM

Scanning Electron Microscopy

Bard Peripheral Vascular, Inc.



BARD® E•LUMINEXX™
BILIARY STENT

Cordis Corporation

S.M.A.R.T.® CONTROL™
NITINOL STENT TRANSHEPATIC
BILIARY SYSTEM

Boston Scientific Corporation

SENTINOL™
SELF-EXPANDING NITINOL
BILIARY STENT SYSTEM

The unique, multi-step electro-polishing technology developed by BARD® reduces microscopic burrs and microcracks

E·LUMINEXX™
VASCULAR STENT

CLINICAL TRIAL OUTCOMES

A Review of Clinical Trial Data[1, 2, 3, 4]

The displayed clinical data are taken from a number of different studies, not a head-to-head study. Each study may have varying patient profiles and protocol structures that may affect the outcome rates set forth below, and therefore is not intended to demonstrate superiority of any one product.

The LUMINEXX® Iliac Clinical Study met the success criteria for the primary endpoint; posterior probability of at least 96% that the 9-month MACE rate was < 25%. MACE included peri-procedural death, TLR and stent segment restenosis and non-study stent. (Non-study stent was added post hoc to the protocol definition of MACE.)





The LUMINEXX® Iliac Clinical Study demonstrated competitive results when considering Primary Patency Rate, Anatomic Success and Mortality Rate.



Consult each respective study for more information on how mortality rates were calculated. Mortality rates within a trial may not be predictive of patient outcomes outside of a controlled clinical trial.

E•LUMINEXX™ VASCULAR & BILIARY STENT

With the...

PerforMAXX® Grip

Order Information

Stent Diameter [mm]	Catheter Length [cm]	Stent Length [mm]	Product Code
7	80	20	ZBM07020
		30	ZBM07030
		40	ZBM07040
		60	ZBM07060
		80	ZBM07080
		100	ZBM07100
	135	20	ZBL07020
		30	ZBL07030
		40	ZBL07040
		60	ZBL07060
		80	ZBL07080
		100	ZBL07100
8	80	20	ZBM08020
		30	ZBM08030
		40	ZBM08040
		60	ZBM08060
		80	ZBM08080
		100	ZBM08100
	135	20	ZBL08020
		30	ZBL08030
		40	ZBL08040
		60	ZBL08060
		80	ZBL08080
		100	ZBL08100
9	80	20	ZBM09020
		30	ZBM09030
		40	ZBM09040
		60	ZBM09060
		80	ZBM09080
		100	ZBM09100
	135	20	ZBL09020
		30	ZBL09030
		40	ZBL09040
		60	ZBL09060
		80	ZBL09080
		100	ZBL09100
10	80	20	ZBM10020
		30	ZBM10030
		40	ZBM10040
		60	ZBM10060
		80	ZBM10080
		100	ZBM10100
	135	20	ZBL10020
		30	ZBL10030
		40	ZBL10040
		60	ZBL10060
		80	ZBL10080
		100	ZBL10100

For All Product Codes: 6F Catheter System; 0.035" Guidewire.

6F BARD S.A.F.E.®◆ Delivery System

PHYSICIAN'S SIGNATURE

1. S.M.A.R.T.® Control™ Nitinol Stent System. Premarket Approval Application Number P020036. Summary of Safety and Effectiveness Data, 2003.
2. Zilver® 635™ Vascular Stent. Premarket Approval Application Number P050017. Summary of Safety and Effectiveness Data, 2006.
3. Wallstent-Uni™ Iliac Endoprosthesis. Premarket Approval Application Number P940019. Summary of Safety and Effectiveness Data, 1996.
4. Ponec D, Jaff MR, Swischuk J, Feiring A, Laird J, Mehra M, Popma JJ, Donohoe D, Firth B, Heim E, Snead D. The nitinol SMART stent vs. Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. *J Vasc Interv Radiol.* 2004;15:911-918.

For more information, contact:

Bard Peripheral Vascular, Inc.
1625 W. 3rd Street
Tempe, AZ 85281
USA
Tel: 1-480-894-9515
1-800-321-4254
Fax: 1-480-966-7062
1-800-440-5376
www.bardpv.com

Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions, and information for use.

◆ S.A.F.E. = Secure Adhesive Free Tip Design.

S11683 Rev. 0

BARD PERIPHERAL VASCULAR